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particularly APOBEC3G, have also been shown to be able to
effectively block retroviral infectivity (32, 47).
TRIM5␣ was first identified as a restriction factor active
against HIV-1 in rhesus monkey cells (36) and later shown to
encode the factors previously described as Ref1 in humans and
Lv1 in monkeys, which are active against a broad range of
divergent retroviruses in a species-specific way (12, 17, 26, 44).
TRIM5 contains a TRIM comprising a RING domain, a B-box
2 domain, and a coiled coil. Multiple splice forms of TRIM5
have been detected that have been predicted to generate a
series of proteins, each shorter from the C terminus (27). The
␣ splice variant additionally encodes a C-terminal B30.2
(SPRY, RFP-like) domain which is essential for antiviral activity. Mutations in the B30.2 domain affect antiviral specificity
and can broaden antiviral activity to previously insensitive retroviruses (21, 24, 36, 45). The viral determinant for sensitivity
to TRIM5␣ is in the CA gene (7, 10, 17, 26, 44, 46). The
simplest model of restriction is that TRIM5␣ interacts with
incoming viral cores via B30.2-CA interactions leading to perturbation of the subsequent CA-dependent events in the viral
life cycle. Indeed, a B30.2 domain-dependent TRIM5–Ntropic MLV (MLV-N) interaction has been demonstrated in
vitro (31, 35). This interaction appears to lead to premature
uncoating of incoming cores, leading to a loss of infectivity
(35). In most cases, restriction by TRIM5␣ leads to a strong
block to viral reverse transcription (17, 26, 34), but in the case
of squirrel monkey TRIM5␣ restriction of simian immunodeficiency virus from rhesus macaque (SIVmac), the restricted
virus reverse transcribes normally (46).
Here we identify a bovine TRIM protein, closely related
to human and simian TRIM5␣ sequences, with strong anti-

Retroviruses rely on host cell biology to complete their life
cycle, and their success throughout mammalian evolution and
their ability to jump between divergent species imply the use of
conserved pathways. The identification and characterization of
these host-virus interactions are expected to enable improvement in animal models of infection, including human immunodeficiency virus (HIV)-AIDS, yield novel antiviral strategies,
and facilitate the use of retroviruses for therapeutic gene delivery. A successful approach has been to characterize examples of species-specific or cell-type-specific retroviral infectivity. This has revealed that, in many cases, poor infection is due
to the presence of dominant inhibitors of retroviral replication,
as opposed to the nonpermissive cells lacking specific activities
required by the virus (3, 7, 10, 20, 34, 39, 40, 46). Evidence for
dominant antiviral factors encouraged the genetic screens that
led to the discovery of the restriction factors APOBEC3G (32),
tripartite motif 5␣ (TRIM5␣) (34), and TRIM-Cyp (22, 30).
The prototype restriction factor is the murine Fv1 protein,
which is derived from an endogenous retroviral gag sequence
(5, 18). The gag-like Fv1 protein targets incoming murine leukemia virus (MLV) capsids (CAs) and blocks infection after
viral DNA synthesis but before the formation of a provirus
(16). There is also evidence to suggest that there may be
dominant antiviral factors that restrict the late stage of the
viral life cycle. The HIV-1 vpu protein has been shown to
overcome a dominant block to viral egress that exists in
human but not simian cells (8, 43). APOBEC3 proteins,
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Lv1/TRIM5␣ (tripartite motif 5␣) has recently emerged as an important factor influencing species-specific
permissivity to retroviral infection in a range of primates, including humans. Old World monkey TRIM5␣
blocks human immunodeficiency virus type 1 (HIV-1) infectivity, and the human and New World monkey
TRIM5␣ proteins are inactive against HIV-1 but active against divergent murine (N-tropic murine leukemia
virus [MLV-N]) and simian (simian immunodeficiency virus from rhesus macaque [SIVmac]) retroviruses,
respectively. Here we demonstrate antiviral activity of the first nonprimate TRIM protein, from cattle, active
against divergent retroviruses, including HIV-1. The number of closely related human TRIM sequences makes
assignment of the bovine sequence as a TRIM5␣ ortholog uncertain, and we therefore refer to it as bovine Lv1.
Bovine Lv1 is closely related to primate TRIM5␣ proteins in the N-terminal RING and B-box 2 domains but
significantly less homologous in the C-terminal B30.2 domain, particularly in the region shown to influence
antiviral specificity. Intriguingly, some viruses restricted by bovine Lv1, including HIV-1 and MLV-N, are
unable to synthesize viral DNA by reverse transcription, whereas restricted HIV-2 makes normal amounts of
DNA. The data support the conclusion that TRIM protein-mediated restriction of retroviral infection is a more
common attribute of mammals than previously appreciated.
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viral activity against a range of divergent retroviruses. We
refer to this protein as bovine Lv1. Our data indicate that
antiretroviral activity of TRIM proteins is not limited to
primates and suggest that such activities may be widespread
in mammals.

MATERIALS AND METHODS

FIG. 1. MDBK cells are differentially permissive to a range of
VSV-G-pseudotyped retroviral vectors. Serial dilutions of VSV-Gpseudotyped, GFP-encoding vectors from MLV-N (E) MLV-B (F),
HIV-1 (}), HIV-2 (‚), SIVmac (Œ), and EIAV (■) were used to infect
MDBK cells. The percentage of infected cells was measured by FACS
48 h after infection. Viral doses were determined by titration onto
CRFK cells, and MOIs were calculated. For example, an MOI of 0.1
infects 10% of the CRFK cells. This experiment is representative of
three replicates with independently prepared virus preparations.

RESULTS
MDBK cells are differentially permissive to a range of VSVG-pseudotyped retroviral vectors. MDBK cells strongly restrict
infection by MLV-N after target cell entry and before reverse
transcription (4, 39). They have also been shown to be poorly
permissive to HIV type 1 (HIV-1) (13). We therefore sought to
examine the permissivity of MDBK cells to infection with other
retroviruses and to identify the antiviral host factors involved.
In order to compare the permissivity of a particular cell line to
that of a series of distantly related viruses, the dose of each
virus must be standardized. Primate lentiviruses are often standardized by measurement of RT activity with an ELISA to
measure a synthetic product of viral RT (9, 11, 14). Such an
assay cannot be reliably used to compare doses of viruses as
unrelated as HIV-1, equine infectious anemia virus (EIAV),
and the gamma retroviruses MLV-N and MLV-B as their RT
enzymes are not likely to be equally active in the assay. We
therefore standardized the viral dose by titration in permissive
Crandell-Reese feline kidney (CRFK) cells. Standardization of
the virus dose for any cell line is likely to be influenced to some
degree by its inevitable differential permissivity to each virus.
Interpretation of such standardization data must therefore be
cautious. However, CRFK cells have been shown to be particularly permissive to a range of viruses (13). Moreover, closely
related viruses such as MLV-N and MLV-B (39) or SIVmac
and HIV-2 (46) have similar titers on these cells. Viral doses
are therefore plotted as multiplicities of infection (MOIs) on
CRFK cells. For example, a multiplicity of 1 of MLV-B will
infect around 66% of CRFK cells and around 10% of MDBK
cells (Fig. 1).
We prepared VSV-G-pseudotyped, GFP-encoding retroviral vectors from MLV-N, MLV-B, HIV-1, HIV-2, EIAV, and
SIVmac and determined their infectious titers on CRFK cells
as previously described (3). Serial dilutions of each virus were
then titrated onto MDBK cells (Fig. 1). MLV-B is high titer on
MDBK cells, and MLV-N is around 3 orders of magnitude less
infectious, as previously described (39). HIV-1 is the most
infectious of the lentiviral vectors, and HIV-2, SIVmac, and
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Cloning of bovine Lv1. Bovine Lv1 was PCR amplified from cDNA prepared
from Madin-Darby bovine kidney (MDBK) cells as previously described (46),
with forward primer LY34 (5⬘-CAGACTGATCACCACCATGGCTTCAGGAA
TCCTG-3⬘ [Bcl1 restriction site underlined and Kozak sequence and ATG start
codon in bold]) and reverse primer LY34 (5⬘-CTTCGATTCGAACTCAACAG
CTTGGTGAGC-3⬘ [Csp45I site underlined]). Primers were designed on the
basis of the bovine expressed sequence tag most closely related to human
TRIM5. All of the PCR products amplified from MDBK cDNA and sequenced
were derived from the gene described herein. The PCR product was cloned into
MLV expression vector pCXCR between the Bc11 and Csp45I sites such that it
was expressed under the control of the MLV long terminal repeat promoter in
infected cells. CXCR also encodes red fluorescent protein (RFP), which is also
expressed in infected cells. Lv1- and RFP-encoding vectors were prepared by
293T transfection with an NB-tropic Moloney MLV packaging construct
(CMVintron) and the vesicular stomatitis virus G envelope protein (VSV-G) as
previously described (17). CRFK cells were transduced with a vector encoding
TRIM5␣ and RFP. Single-cell clones were isolated by limiting dilution, and
positive clones were identified by red fluorescence microscopy. Positive clones
were infected with green fluorescent protein (GFP)-encoding virus and, 48 h
after that, assayed for green fluorescence by fluorescence-activated cell sorter
(FACS) as previously described (17). The bovine Lv1 sequence was determined
by sequencing three independent clones. DNA sequence analysis was performed
with DNA Dynamo software (Blue Tractor Software, North Wales, United
Kingdom).
Phylogenetic analysis. Amino acid sequences were aligned in ClustalW (38),
and the resulting alignment was manually adjusted. Uninformative regions and
regions of low homology were removed to create a final alignment that was 487
amino acids in length. Bootstrapped phylogenies were constructed with 1,000
replicates of the neighbor-joining algorithm as implemented in PAUP 4.0 (37)
and the Blosum62 amino acid transition matrix.
Viral vector preparation and infectivity assays. VSV-G-pseudotyped, GFPencoding retroviral vectors were prepared as previously described (3, 46), by
triple transfection of 293T cells. Virus infectivity was measured by titrating
serially diluted virus onto 105 cells per well in six-well plates. Infected cells
were enumerated 48 h later by measuring GFP expression by FACS (BD
Biosciences).
Disruption of Lv1 expression with small interfering RNA (siRNA). Disruption
of bovine Lv1 expression with siRNA was performed by transfecting 2.5 ⫻ 104
MDBK cells with siRNA oligonucleotides (QIAGEN) by using Oligofectamine
(Invitrogen) according to the manufacturer’s instructions in 24-well plates. The
siRNA oligonucleotide sequence for bovine Lv1 was AUGCGAAUGUCAUCAU
AAA. The irrelevant control oligonucleotide sequence was AGAGUUUAAUCA
GCUACGA. Forty-eight hours later, cells were split 1:6 and incubated overnight.
Cells were infected with serial dilutions of GFP-encoding MLV-N, B-tropic MLV
(MLV-B), HIV-1, HIV-2, SIVmac, or EIAV prepared as previously described (3, 17,
46). Infected cells were enumerated by analysis of GFP expression by FACS (BD
Bioscience). Titers of lentiviruses were calculated in infectious units per nanogram
of reverse transcriptase (RT), determined by enzyme-linked immunosorbent assay
(ELISA; CavidiTech, Uppsala, Sweden). Doses of MLV-N and MLV-B were equalized on murine SC1 cells, and titers are calculated as numbers of infectious units per
104 SC1 infectious units.
Quantitative PCR. A TaqMan PCR to measure viral DNA synthesis was
performed with primer and probe sequences specific to GFP as previously described (3). Cells (105) were infected in six-well plates in triplicate with equivalent doses of DNase-treated virus. Six hours after infection, total DNA was
extracted from two samples with a DNeasy kit (QIAGEN, Chatsworth, CA). The
third sample was subjected to FACS analysis 48 h after infection to enumerate
infected cells. DNA (100 ng) was subjected to TaqMan quantitative PCR as
previously described (3, 42).
Nucleotide sequence accession number. The Lv1 sequence described here has
been submitted to GenBank and assigned accession no. DQ380509.
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FIG. 3. Reduction of Lv1 levels in MDBK cells increases their permissivity to viral infection. (A and B) Titers of MLV-N, MLV-B, HIV-1
HIV-2, SIVmac, and EIAV on MDBK cells after transfection of bovine TRIM5␣-specific siRNA (black bars) or untreated MDBK cells (white
bars). The viral doses used were chosen to infect between 0.5 and 5% of the cells in the absence of siRNA. MLV-N and MLV-B doses were
equalized by infection of permissive murine SC1 cells and are plotted as infectious units (i.u.) per milliliter on MDBK cells. RT activity of HIV-1,
HIV-2, SIVmac, and EIAV was measured by ELISA, and titers are plotted as infectious units per nanogram of RT. Each error bar indicates the
standard error of the mean of three repetitions.

and apes. The TRIM sequences from cattle and pigs appear to be
relatively closely related, but the relationship of these proteins to
the larger subset of TRIM5␣-like genes is more difficult to discern, and it is not clear from this analysis whether the TRIM
sequences from pigs and cows are orthologous with TRIM5␣ or
with another closely related TRIM protein in humans.
Reduction of bovine Lv1 levels in MDBK cells increases
their permissivity to viral infection. We directly examined the
role of bovine Lv1 in the poor permissivity of bovine cells by
reducing its expression with siRNA and measuring viral infectivity. Treatment with siRNA directed against bovine Lv1 specifically increased MLV-N, HIV-1, HIV-2, and SIVmac infectivity
but not MLV-B or EIAV infectivity (Fig. 3A and B). Transfection
of an irrelevant siRNA had no effect on the infectivity of any of
the viruses (data not shown). siRNA to Lv1 did not rescue
MLV-N infectivity to the level of MLV-B infectivity, suggesting
an incomplete reduction of bovine Lv1 expression, consistent with
the fact that MDBK cells are difficult to transfect with siRNA
(data not shown). These data suggest that bovine Lv1 has a broad
antiviral effect and is largely responsible for the poor permissivity
of bovine cells to retroviral infection.
Expression of bovine Lv1 in permissive feline cells renders
them able to restrict a range of divergent retroviruses. To
further examine the ability of bovine Lv1 to restrict viral infection, we expressed the protein in CRFK cells by using an
MLV vector as previously described (17). In these experiments, the feline cells expressing the bovine Lv1 protein are
clonal and coexpress a fluorescent marker gene. We called
these cells CRFKboLv1. We then compared the permissivity of
CRFKboLv1 and unmodified CRFK cells to infection by a
range of retroviruses (Fig. 4). Expression of bovine Lv1 renders CRFK cells almost 2 orders of magnitude less permissive
to MLV-N. As expected, the infectivity of MLV-B is not significantly affected by bovine Lv1 expression. These data are
reminiscent of the strong restriction of MLV-N by the human
and Agm TRIM5␣ proteins and the insensitivity of MLV-B to

FIG. 2. Identification of a gene for bovine Lv1. (A) Bovine Lv1 sequence (Bo) aligned with the human (Hu) and Agm TRIM5␣ sequences. Domains
are according to reference 34. (B) Phylogenetic tree showing the relationship of bovine Lv1 to 10 primate TRIM5␣ genes, to related TRIM-encoding
genes in humans (those for TRIM6, TRIM22, and TRIM34), and to TRIM5␣-like proteins identified in mice and domestic pigs. Bootstrap values, based
on 1,000 neighbor-joining replicates, are shown for each node where support was greater than 60%. Asterisk, identical residue; colon, conserved substitution; period, semiconserved substitution; gap, no conservation.
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the horse lentivirus EIAV all have similar low infectivities on
these cells, in comparison to CRFK cells.
Identification of a bovine Lv1 gene. The block to MLV-N in
MDBK cells is after viral entry and before viral reverse transcription and is characteristic of blocks to retroviral infection
mediated by primate Lv1/TRIM5␣ proteins. We therefore hypothesized that an Lv1-like activity exists in MDBK cells, despite the fact that TRIM5␣ had previously been observed only
in primates. Consistent with this hypothesis, we were able to
clone and sequence a gene closely related to human TRIM5␣
expressed in MDBK cells. Alignment of bovine, human, and
African green monkey (Agm) sequences reveals that the bovine protein is highly homologous to human and simian proteins, particularly in the N-terminal RING and B-box 2 domains and in certain parts of the B30.2 domain (Fig. 2A).
Notably, the region of the B30.2 domain previously shown to
determine the antiviral specificity of primate TRIM5␣ proteins, around residues 320 to 350 (21, 24, 29, 36, 45), is not
conserved. Furthermore, an insertion in the bovine sequence,
residues 349 to 375, is reminiscent of a 20-amino-acid insertion in
the Agm B30.2 domain, relative to the human and rhesus sequences, although there is no homology between the Agm and
bovine insertions. Interestingly, the inserted sequence in Agm has
been implicated in its antiviral specificity (21).
We further examined the evolutionary relationship of the
bovine Lv1 sequence to primate TRIM5␣ sequences by constructing a phylogenetic tree (Fig. 2B). We also included three
further human TRIM sequences (TRIM6, TRIM22, and
TRIM34) in this analysis as they are closely related to TRIM5
in humans, are arranged in tandem on chromosome 11, and on
the basis of their close homology, are likely to represent duplications of an ancient TRIM sequence. Finally, we included
the murine and porcine expressed sequence tags most closely
related to primate TRIM5␣ genes. As expected, primate
TRIM5␣ sequences cluster according to primate phylogeny into
three groups representing New World and Old World monkeys
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FIG. 4. Expression of bovine Lv1 in permissive feline cells renders
them able to restrict a range of retroviruses. Serial dilutions of the
indicated VSV-G-pseudotyped, GFP-encoding viruses were titrated
onto cloned CRFK cells expressing bovine Lv1 (boLv1; open symbols)
or unmodified CRFK cells as a control (solid symbols). Percentages of
infected cells were measured by FACS 48 h after infection. RT activities of HIV-1, HIV-2, SIVmac, and EIAV were measured by ELISA
in nanograms (ngRT). Results are representative of two independent
experiments performed with two independent virus preparations and
two clones of CRFKboLv1 cells. i.u., infectious units.

all of the TRIM5␣ proteins tested thus far. We also tested the
permissivity of CRFKboLv1 to HIV-1, HIV-2, SIVmac, and
EIAV GFP-encoding vectors (Fig. 4). HIV-1, HIV-2, and
SIVmac are all restricted by around 10-fold in CRFKboLv1
compared to unmodified CRFK cells. EIAV is weakly restricted by overexpression of bovine Lv1. However, the lack of
an effect on EIAV infectivity after transfection of bovine Lv1specific siRNA (Fig. 3) suggests that bovine Lv1 does not
significantly contribute to the poor infectivity of EIAV in
MDBK cells and this small inhibition is likely to be due to the
expansion of antiviral specificity often seen when factors are
overexpressed (6, 23, 46). Data in Fig. 4 support the notion that
much of the poor permissivity of bovine cells to retroviral
infectivity is due to the expression of a bovine TRIM5␣-like
Lv1 protein with broad antiviral specificity.
Bovine Lv1 restriction of viral infection can be before or
after reverse transcription. TRIM5␣ usually restricts retroviral
infectivity very early after target cell entry, before significant
viral reverse transcription (17, 26, 34). An exception is
TRIM5␣ from New World squirrel monkeys, which strongly
restricts SIVmac infectivity, despite normal levels of SIVmac
DNA synthesis (46). In order to examine whether bovine Lv1

FIG. 5. Restriction of viral infection by bovine Lv1 can be before or
after reverse transcription. (A) Measurement of viral cDNA synthesis
after bovine Lv1-restricted and unrestricted infection by TaqMan
quantitative PCR. CRFK cells (black bars) or CRFK cells expressing
bovine Lv1 were infected in triplicate with MOIs of viruses of around
0.2, determined on unmodified CRFK cells. At 6 h after infection,
DNA was extracted from two samples and subjected to quantitative
PCR in duplicate with primers and a probe specific for GFP. (B) The
percentage of infected cells in the third sample was measured by FACS
48 h after infection. Errors are standard errors of the means. Results
are representative of two independent experiments performed with
two different CRFKboLv1 clones.

is able to block viral reverse transcription, we infected CRFK
cells or CRFK cells expressing bovine Lv1 and measured viral
DNA by TaqMan quantitative PCR 6 h after exposure to virus
as previously described (3) (Fig. 5A). Cells were infected in
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triplicate, and 6 h after infection two samples were DNA extracted for PCR. The third sample was subjected to FACS
analysis 48 h after infection to measure infected cells (Fig. 5B).
We used a fixed dose of virus equivalent to a MOI of around
0.2 on unmodified CRFK cells. Expression of bovine Lv1 led to
a significant reduction in MLV-N DNA synthesis, compared to
MLV-B, as it does in bovine cells (4). HIV-1 DNA synthesis is
also reduced by around 10-fold, which corresponds to a 10-fold
reduction in infectivity on the bovine Lv1-expressing cells. In
contrast, there was moderate inhibition of viral DNA synthesis
by SIVmac and no inhibition for HIV-2, despite the observed
10-fold reduction in infectivity. The consequence of restriction
by bovine Lv1 therefore depends on the virus rather than on
the Lv1 protein, and bovine Lv1 is able to restrict virus before
or after reverse transcription.

We have identified a bovine TRIM protein showing significant homology to the primate restriction factor TRIM5␣ and
demonstrated that it strongly influences the permissivity of
bovine cells to retroviral infection. Although this function
strongly suggests a relationship with TRIM5␣ proteins in primates, it is difficult to determine with absolute certainty
whether the bovine gene represents an ortholog of primate
TRIM5␣. Phylogenetic analysis places the bovine sequence
between primate TRIM5␣ sequences and the closely related
human TRIM6, TRIM22, and TRIM34 proteins (Fig. 2B).
However, TRIM proteins with antiviral function are likely to
undergo rapid evolution because of strong positive selection
(29), and consequently their evolutionary relationships
across species may have been obscured. Furthermore, the
chromosomal arrangement of TRIM5, TRIM6, TRIM22,
and TRIM34 in tandem in humans suggests a history of
duplication for TRIM genes that not only obscures synteny
but may have differed across mammalian lineages, making a
definition of orthology based on the identification of syntenous regions in different species difficult if not impossible.
Nevertheless, such an assignment is largely semantic, particularly since sequence homology suggests that TRIM5␣ is
likely to be derived from duplication of TRIM6 or vice
versa. The overriding observation is that the bovine sequence is closely related to primate TRIM5␣ proteins and
has a similar antiviral activity. On this basis, we refer to the
bovine protein as bovine Lv1.
Alignment of bovine and primate sequences demonstrates a
high level of conservation in the N-terminal RING and B-box
2 domains but lower homology in the C-terminal B30.2 domain
(Fig. 2A). The role of the RING and B-box 2 domains in
restriction remains unclear. High conservation of the RING
domain suggests that it is important for TRIM5 function.
RING domains are found in E3 ligases for proteins such as
ubiquitin or SUMO, suggesting that modification of incoming
cores may underlie the antiviral mechanism, although this remains controversial (15, 24, 25). Remarkably, an inactive allele
of TRIM5␣ carrying the RING domain polymorphism H43Y
has recently been described in the human population (28). The
inactivity of this protein also supports a role for the RING
domain in restriction, as well as a nonessential role for

TRIM5␣ in humans. The bovine sequence has a conservative
change to asparagine at this position (Fig. 2).
Analyses of primate TRIM5␣ B30.2 domain sequences reveal variable regions under selection in recent primate evolution, presumably under pressure from pathogenic endogenous
or exogenous viruses (29, 33). Remarkably, both the bovine
and Agm Lv1 proteins restrict HIV-1, HIV-2, SIVmac, EIAV,
and MLV-N but not MLV-B (Fig. 1 and 4) (10). It therefore
seems that Lv1 antiviral determinants unrelated at the sequence level can be closely related in terms of antiviral specificity. The fact that MDBK cells, and therefore bovine Lv1,
restrict MLV-N but not MLV-B with specificity for amino acid
110 in the MLV CA (4) demonstrates that the viral restriction
sensitivity determinant is in the CA protein, as it is for other
Lv1/TRIM5␣ alleles (7, 10, 17, 26, 44, 46). These observations
support the notion that Lv1/TRIM5␣ is an effective antiviral,
targeting CA from a broad array of unrelated retroviruses to
block infection. It remains unclear how HIV-1 has escaped
restriction by human TRIM5␣ and also why MLV-B and
Moloney MLV are insensitive to any of the TRIM5␣ alleles
thus far tested. One possibility is that MLV’s relative insensitivity to TRIM5␣ is related to the fact that the MLV CA does
not have the exposed loop on its surface (19) that is targeted by
TRIM5␣ (11, 14, 46), making it easier for MLV to escape
TRIM5␣ activity.
Most TRIM5␣-restricted viruses make very little viral DNA,
indicating that the block to infection is very early after the virus
has entered the target cell. However, in some cases, exemplified by restriction of SIVmac by squirrel monkey TRIM5␣, the
restricted virus is able to reverse transcribe normally (46). The
murine gag-like restriction factor Fv1 is also able to block
MLV infection after reverse transcription, and this is conserved when Fv1 is expressed in human cells (4). Despite the
apparently later interaction between Fv1 and virus, Fv1 and
TRIM5␣ can compete for incoming virus (23). This and the
fact that bovine Lv1 restricts MLV-N and HIV-1 before reverse transcription, whereas restricted HIV-2 is able to synthesize normal levels of DNA (Fig. 5), suggest that the timing of
the block is dependent on both the factor and the virus. It
seems likely, therefore, that restriction factors interact with
incoming virus very early after entry and it is the consequences
of these interactions that vary. In some cases, the restricted
virus is unable to reverse transcribe whereas in other cases
restricted virus is able to make normal levels of DNA despite
the fact that it will ultimately be noninfectious. These observations are consistent with TRIM5␣ interacting with incoming
CA and perturbing the normal rearrangement or uncoating
events that are important during reverse transcription and
trafficking.
The isolation of a broadly effective antiviral TRIM protein
from cattle indicates that innate immune activity of TRIM
proteins extends beyond primates, and it will be interesting to
examine the antiviral activity of other TRIM molecules from
divergent vertebrates. Our data suggest that antiviral TRIM
proteins are likely to be widespread within mammals and represent a conserved mechanism of protection from pathogenic
retroviruses. Furthermore, the ability of drugs such as arsenic
trioxide (2, 17) or cyclosporine (1, 41) to manipulate viral
sensitivity to host restriction factors suggests that these pathways might be a target for novel therapeutics.
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